Genelux Q2 net loss widens

Genelux

07/08/2025 21:31

Overview

Genelux Q2 net loss of $7.5 mln beats analyst expectations, per LSEG data

Company advances Olvi-Vec towards potential registration in platinum-resistant/refractory ovarian cancer

In July, Eric Groen appointed as General Counsel, Corporate Secretary, Chief Compliance Officer, and Head of Business Development to strengthen leadership team

Outlook

Company anticipates cash runway into Q3 2026

Result Drivers

CLINICAL TRIAL COSTS - Increase in R&D expenses driven by Phase 3 OnPrime trial costs

LEADERSHIP ENHANCEMENT - Appointment of Eric Groen to strengthen executive team

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
Beat
-$7.46 mln
-$7.81 mln (6 Analysts)
Q2 Income from Operations
Beat
-$7.79 mln
-$7.86 mln (5 Analysts)
Q2 Operating Expenses
$7.79 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Genelux Corp is $13.00, about 72.4% above its August 6 closing price of $3.59

Press Release: ID:nGNXbh9TXt

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)